Jörg Herold

Dr. Jörg Herold

orcid

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 June 2011 in Journal of Histochemistry & Cytochemistry
Verified
Journal Article
Open access
AFAlexander Francke
Alexander Francke
JHJörg Herold
Jörg Herold
SWSoenke Weinert
Soenke Weinert
RSRuth H. Strasser
Ruth H. Strasser
RBRuediger C. Braun-Dullaeus
Ruediger C. Braun-Dullaeus
Monocytes are involved in a wide range of physiological and pathological processes, many of which are studied in mouse models. Current protocols to isolate murine monocytes are few and result in unsatisfactory cell yield and purity. Here, we describe a novel approach to efficiently differentiate large numbers of mature inflammatory monocytes from heterogeneous bone marrow cell suspensions. Bone marrow cell suspensions were isolated by flushing femurs and tibias from Balb/c and C57Bl/6 mice, supplemented with macrophage colony–stimulating factor (M-CSF), and were cultured on ultra-low attachment surfaces to inhibit adherence-mediated maturation. Cells were harvested at indicated time points, underwent time-line analysis of the differentiation processes, and were subsequently extensively phenotyped to verify their monocytotic properties. In order to confirm downstream compatibility, we tested for typical monocyte behavior. Our protocol yielded 24 ± 6 × 106 differentiated cells per donor mouse, 10-fold higher than yields obtained using previously described peripheral blood isolation methods. Differentiated cells consisted of approximately 47% ± 12% monocytes, the rest being mature macrophages. We increased monocyte purity to 86% ± 6% by depleting adherent macrophages. Our findings indicate that bone marrow–derived monocytes (BMDMs) are an attractive tool to study, for example, the innate and adaptive immune system, atherosclerosis, and cellular migration during infection. Moreover, BMDM transplantation could be used to test novel, therapeutic in vivo approaches in mice disease models.

1 April 2018 in Vasa
Verified
Journal Article
Closed access
MSMaria Stolt
Maria Stolt
RBRuediger Braun-Dullaeus
Ruediger Braun-Dullaeus
JHJörg Herold
Jörg Herold
In addition to haematoma and arteriovenous fistula, the iatrogenic pseudoaneurysm is a common complication of vascular access that is caused by a perforation in the arterial wall. Iatrogenic pseudoaneurysms can progress in size and lead to rupture and active bleeding. Over the previous few decades, therapeutic methods have evolved from surgical repair to less invasive options, such as ultrasound-guided compression therapy (UGCT) and ultrasound-guided thrombin injection (UGTI). This paper presents an overview of the diagnostic and treatment modalities used in femoral pseudoaneurysms as well as a comprehensive summary of previous studies that analysed the success and complication rates of UGCT and UGTI.

1 January 2011 in Vasa
Verified
Journal Article
Closed access
JHJörg Herold
Jörg Herold
SBS Brucks
S Brucks
HBH Boenigk
H Boenigk
SSS M Said
S M Said
RBRuediger C. Braun-Dullaeus
Ruediger C. Braun-Dullaeus
Thrombin injection is frequently used to occlude iatrogenic pseudoaneurysms in larger vessels, but has never successfully been used in the radial artery location. Here we report the use of this treatment in a patient with radial artery pseudoaneurysm following coronary intervention. After Doppler sonographic visualization of the pseudoaneurysm cavity and its neck, an ultrasound-guided transcutaneous injection of thrombin was carried out. Immediately after the injection, the pseudoaneurysm was completely clotted and Doppler measurement confirmed the stop of blood flow. The result suggests that ultrasound-guided injection of thrombin into a radial artery pseudoaneurysm following coronary intervention is a feasible alternative to surgical intervention.

12 February 2014 in Heart and Vessels
Verified
Journal Article
Closed access
PDF file
MCMarian Christoph
Marian Christoph
JHJörg Herold
Jörg Herold
ABAnna Berg-Holldack
Anna Berg-Holldack
TRThomas Rauwolf
Thomas Rauwolf
Tjalf ZiemssenTjalf Ziemssen
Tjalf Ziemssen
RBRuediger C. Braun-Dullaeus
Ruediger C. Braun-Dullaeus

25 March 2006 in Langenbeck's Archives of Surgery
Verified
Journal Article
Closed access
PDF file
JHJörg Herold
Jörg Herold
HTHarald Tillmanns
Harald Tillmanns
ZXZhou Xing
Zhou Xing
RSRuth H. Strasser
Ruth H. Strasser
RBRuediger C. Braun-Dullaeus
Ruediger C. Braun-Dullaeus

20 December 2017 in BMC Cardiovascular Disorders
Verified
Journal Article
Open access
PDF file
JHJörg Herold
Jörg Herold
VHVasiliki Herold-Vlanti
Vasiliki Herold-Vlanti
MSMohammad Sherif
Mohammad Sherif
BLBlerim Luani
Blerim Luani
CBChristin Breyer
Christin Breyer
RBRuediger C. Braun-Dullaeus
Ruediger C. Braun-Dullaeus
Transcatheter aortic valve replacement (TAVR) has been demonstrated to be an established therapy for high-risk, inoperable patients with severe symptomatic aortic valve stenosis. For patients with moderate surgical risk, TAVR is equivalent to conventional aortic valve surgery. However, atrial fibrillation (AF) is also present in many of these patients, thus requiring post-implantation oral anticoagulation therapy in addition to the inhibition of thrombocyte aggregation, which poses the risk of bleeding complications. The aim of our work was to investigate the influence of AF on mortality and the occurrence of bleeding, vascular and cerebrovascular complications related to TAVR according to the VARC-2 criteria. Two hundred eighty-three patients who underwent TAVR between March 2010 and April 2016 were retrospectively examined. In total, 257 patients who underwent transfemoral access were included in this study. The mean patient age was 81 ± 6 years, 54.1% of the patients were women, and 42.4% had pre-interventional AF. Compared to patients with sinus rhythm (SR, n = 148), patients with AF (n = 109) had an almost three-fold higher incidence of major vascular complications (AF 14.7% vs. SR 5.4%, p = 0.016) and life-threatening bleeding (AF 11.9% vs. SR 4.1%, p = 0.028) during the first 30 post-procedural days. However, the rate of cerebrovascular complications (AF 3.7% vs. SR 2.7%, p = 0.726) did not significantly differ between the two groups. Overall mortality was significantly higher in patients with AF during the first month (AF 8.3% vs. SR 2.0%, p = 0.032) and the first year (AF 28.4% vs. SR 15.3%; p = 0.020) following TAVR. Patients with AF had significantly more severe bleeding complications after TAVR, which were significantly related to mortality. Future prospective randomized studies must clarify the optimal anticoagulation therapy for patients with AF after TAVR. DRKS00011798 on DRKS (Date 17.03.2017).